Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study.
Mian H, Seow H, Pond GR, Gayowsky A, Foley R, Balistky A, Ebraheem M, Cipkar C, Sapru H, Mohyuddin GR, Hadidi SA, Visram A. Mian H, et al. Among authors: visram a. Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00065-X. doi: 10.1016/j.clml.2024.02.006. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38431522
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK. Goldman-Mazur S, et al. Among authors: visram a. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):e104-e111.e1. doi: 10.1016/j.clml.2023.11.008. Epub 2023 Nov 27. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38135634
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, McCurdy A, LeBlanc R, Song K, Mian H, Louzada M, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Venner C, Kaedbey R, Gul E, Reece D. Visram A, et al. Blood Cancer J. 2023 Dec 8;13(1):181. doi: 10.1038/s41408-023-00946-z. Blood Cancer J. 2023. PMID: 38065967 Free PMC article.
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: visram a. Blood Cancer J. 2023 Aug 28;13(1):129. doi: 10.1038/s41408-023-00888-6. Blood Cancer J. 2023. PMID: 37635183 Free PMC article. No abstract available.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
LeBlanc R, Mian H, Reece D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, Sebag M, Song K, Louzada M, Kotb R, Visram A, White D, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kaedbey R, Gul E, Venner C. LeBlanc R, et al. Among authors: visram a. Eur J Haematol. 2023 Nov;111(5):815-823. doi: 10.1111/ejh.14082. Epub 2023 Aug 13. Eur J Haematol. 2023. PMID: 37574220
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: visram a. Blood Cancer J. 2023 Jul 20;13(1):111. doi: 10.1038/s41408-023-00883-x. Blood Cancer J. 2023. PMID: 37474492 Free PMC article.
97 results